Related Experiment Video
Updated: Jan 28, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain
Anne Hansen Ree1,2, Vigdis Nygaard3, Hege G Russnes4,5
1Department of Oncology, Akershus University Hospital, Lørenskog, Norway. a.h.ree@medisin.uio.no.
Abstract:
Most patients whose large bowel cancer has spread to other organs do not respond to immune therapy. We detected a rare gene mutation, termed 9p24.1 copy-number gain (CNG), in an otherwise incurable colorectal cancer that provoked an immune therapy response. We identified this gene mutation by gene-panel sequencing of DNA from a liver metastasis biopsy from a patient who had disease refractory to standard therapies. Following immune checkpoint blockade (ICB) with pembrolizumab (anti-PD-1), the patient experienced conversion of the tumor phenotype from one with epithelial features to that of an inflamed microenvironment, detected by high-resolution RNA sequencing. Circulating tumor DNA disappeared over the first weeks of therapy. As assessed by standard radiographic measurement, the patient had a partial response that was durable. This patient's response may support the use of histology-agnostic ICB in solid tumors that carry the rare 9p24.1 CNG.
Insights
A rare 9p24.1 copy-number gain (CNG) mutation in colorectal cancer unexpectedly responded to immune checkpoint blockade (ICB). This finding offers hope for previously untreatable metastatic cancers.
Area of Science:
- Oncology
- Genetics
- Immunotherapy
Background:
- Most metastatic colorectal cancers do not respond to immune therapies.
- Immune checkpoint blockade (ICB) is a promising cancer treatment, but efficacy is limited in certain tumor types.
Observation:
- A patient with incurable colorectal cancer and a rare 9p24.1 copy-number gain (CNG) mutation was treated with ICB (pembrolizumab).
- Gene-panel sequencing identified the 9p24.1 CNG in a liver metastasis biopsy.
- High-resolution RNA sequencing revealed a phenotypic shift in the tumor from epithelial to an inflamed microenvironment post-treatment.
Findings:
- The patient experienced a durable partial radiographic response to ICB.
- Circulating tumor DNA levels decreased significantly after initiating therapy.
- The 9p24.1 CNG mutation was associated with a positive response to immunotherapy.
Implications:
- The 9p24.1 CNG mutation may serve as a predictive biomarker for ICB response in solid tumors.
- This case supports the potential use of histology-agnostic ICB for tumors harboring this rare genetic alteration.
- Further research is warranted to explore the therapeutic potential of targeting 9p24.1 CNG in cancer treatment.
More Related Videos
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
Related Concept Videos
Piaget's Stage 1 of Cognitive Development
Exploration...
Neuromuscular Junction And Blockade
Gain
Gain:
Suppose Vin is the input and Vout is the output signal to a circuit.
Locus of Control
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
The Colonization of Land